09.24.26 -- Why ING Feels Different

As innovative therapies move beyond home markets, early planning across regulators and geographies helps avoid costly delays and protect trial budgets.

Improve budget oversight, forecast costs more accurately, and maintain a clear audit trail to minimize surprises and streamline CRO change orders.

Discover how specialized expertise, innovative technology, and purpose-built resources can come together to accelerate early-phase clinical research and deliver quality, efficient outcomes.

IRB approval does not have to be defined by delays or confusion. Learn how expert guidance, regulatory support, and modern technology can help research teams move forward with greater efficiency.

Strategic planning, data-driven decisions, and global coordination accelerate clinical timelines while ensuring quality. Explore risk-based monitoring and practical ways to overcome complexity.

A 2026 executive order is fast-tracking psychedelic therapies for depression, PTSD, and addiction. Understand what this regulatory shift means for your next clinical trial.

Learn how evolving trial designs are changing RTSM requirements and driving demand for greater flexibility, traceability, and execution quality.

Investigational products present a distinctly high-risk environment for labeling and barcoding. Explore best practices for barcoding solutions that allow for improved medication safety in clinical trials.

As ADC development grows more complex, sponsors must align safety, dose optimization, global trial design, regulatory strategy and CMC readiness early to reduce risk and accelerate approval.

Learn to overcome solubility challenges and utilize flexible development strategies to transition innovative treatments from early-phase trials to commercialization while ensuring patient safety.